These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 11006917)

  • 1. Beyond the UKPDS: in search of the optimal strategy for the treatment of type 2 diabetes.
    Riccardi G
    Nutr Metab Cardiovasc Dis; 2000 Jun; 10(3):104-7. PubMed ID: 11006917
    [No Abstract]   [Full Text] [Related]  

  • 2. [How effectively should hyperglycemia be treated in a type 2 diabetes patient?].
    Eriksson J
    Duodecim; 2009; 125(13):1387-94. PubMed ID: 19678494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical practice. Initial management of glycemia in type 2 diabetes mellitus.
    Nathan DM
    N Engl J Med; 2002 Oct; 347(17):1342-9. PubMed ID: 12397193
    [No Abstract]   [Full Text] [Related]  

  • 4. Basic approach to managing hyperglycemia for the nonendocrinologist.
    Deeg MA
    Am J Cardiol; 2005 Aug; 96(4A):37E-40E. PubMed ID: 16098842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of type 2 diabetes: one extreme to another.
    Zaidi S
    Arch Intern Med; 2009 Jul; 169(13):1246-7; author reply 1247. PubMed ID: 19597079
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacotherapy of diabetes mellitus: implications for the prevention and treatment of cardiovascular disease.
    Ragucci E; Zonszein J; Frishman WH
    Heart Dis; 2003; 5(1):18-33. PubMed ID: 12549986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beneficial effects of combined treatment with rosiglitazone and exercise on cardiovascular risk factors in patients with type 2 diabetes.
    Kadoglou NP; Iliadis F; Liapis CD; Perrea D; Angelopoulou N; Alevizos M
    Diabetes Care; 2007 Sep; 30(9):2242-4. PubMed ID: 17586747
    [No Abstract]   [Full Text] [Related]  

  • 8. Recommendations from the Canadian Diabetes Association. 2003 guidelines for prevention and management of diabetes and related cardiovascular risk factors.
    Harris SB; Lank CN
    Can Fam Physician; 2004 Mar; 50():425-33. PubMed ID: 15318682
    [No Abstract]   [Full Text] [Related]  

  • 9. Optimizing antidiabetic treatment options for patients with type 2 diabetes mellitus and cardiovascular comorbidities.
    Malesker MA
    Pharmacotherapy; 2008 Feb; 28(2):193-206. PubMed ID: 18225965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diabetes and vascular disease.
    Deedwania P; Srikanth S
    Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):127-38. PubMed ID: 18095912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of type 2 diabetes].
    Daubresse JC
    Rev Med Brux; 2004 Feb; 25(1):22-8. PubMed ID: 15053151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Postprandial hyperglycemia. Cardiovascular risks and new therapeutic strategies].
    Sjöholm A
    Lakartidningen; 2001 Feb; 98(9):937-40. PubMed ID: 11292972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Primary combined oral antidiabetic therapy in type-2 diabetes mellitus].
    Winkler G; Baranyi E
    Orv Hetil; 2002 Oct; 143(43):2441-7. PubMed ID: 12455146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The effect of metformin on late diabetic complications and cardiovascular events in obese patients with type 2 diabetes].
    Christiansen AL; Madsbad S
    Ugeskr Laeger; 2002 Apr; 164(15):2022-4. PubMed ID: 11984999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of diabetes in cardiovascular patients: diabetic heart disease.
    Peter R; Cox A; Evans M
    Heart; 2008 Mar; 94(3):369-75. PubMed ID: 18276822
    [No Abstract]   [Full Text] [Related]  

  • 16. [Arterial risk in type 2 diabetes: from mega-trials to prescription].
    Bonnet F; Moulin P
    Rev Prat; 2003 May; 53(10):1095-101. PubMed ID: 12846030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of oral anti-diabetic agents in modifying cardiovascular risk factors.
    Shin JJ; Rothman J; Farag A; McFarlane SI; Sowers JR
    Minerva Med; 2003 Dec; 94(6):401-8. PubMed ID: 14976468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of post-prandial blood glucose excursions in type 1 and type 2 diabetes mellitus.
    Slama G
    Int J Clin Pract Suppl; 2000 Sep; (112):9-12. PubMed ID: 11064945
    [No Abstract]   [Full Text] [Related]  

  • 19. Does intensive glycemic control improve cardiovascular outcomes?
    Pendergrass M
    Nat Clin Pract Endocrinol Metab; 2008 Oct; 4(10):529. PubMed ID: 18806805
    [No Abstract]   [Full Text] [Related]  

  • 20. [Intensive blood glucose lowering to reduce cardiovascular risk: pro].
    Martin S
    Dtsch Med Wochenschr; 2009 May; 134(20):1060. PubMed ID: 19421929
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.